UA95103U - METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION - Google Patents

METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION

Info

Publication number
UA95103U
UA95103U UAU201407167U UAU201407167U UA95103U UA 95103 U UA95103 U UA 95103U UA U201407167 U UAU201407167 U UA U201407167U UA U201407167 U UAU201407167 U UA U201407167U UA 95103 U UA95103 U UA 95103U
Authority
UA
Ukraine
Prior art keywords
placental
dysfunction
fetal
placentarial
treatment
Prior art date
Application number
UAU201407167U
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAU201407167U priority Critical patent/UA95103U/en
Publication of UA95103U publication Critical patent/UA95103U/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В способі лікування плацентарної дисфункції шляхом використання комплексної терапії попередньо визначають рівень вільного естріолу, плацентарного лактогену, показники стану плода та розміри плода, і за умови порушення синтезу гормонів та зменшення розмірів плода призначають препарати α-ліпоєвої кислоти етилендіамінової солі та препарати α-аміно-d-гуанідиновалеріанової кислоти впродовж 10-14 днів під контролем гормонів плаценти та розмірів плода у вагітних із плацентарною дисфункцією у терміні вагітності 28-34 тижні.In the method of treating placental dysfunction by the use of complex therapy, pre-determine the level of free estriol, placental lactogen, indicators of fetal status and fetal size, and in the case of impaired hormone synthesis and reduction of fetal size, prescribe α-lipoic acid ethylenediamine salts and d-α preparations -guanidinoleric acid for 10-14 days under the control of placental hormones and fetal size in pregnant women with placental dysfunction at 28-34 weeks of gestation.

UAU201407167U 2014-06-25 2014-06-25 METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION UA95103U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201407167U UA95103U (en) 2014-06-25 2014-06-25 METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201407167U UA95103U (en) 2014-06-25 2014-06-25 METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
UA95103U true UA95103U (en) 2014-12-10

Family

ID=52681292

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201407167U UA95103U (en) 2014-06-25 2014-06-25 METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION

Country Status (1)

Country Link
UA (1) UA95103U (en)

Similar Documents

Publication Publication Date Title
Imanieh et al. Oxytocin has therapeutic effects on cancer, a hypothesis
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112016017700A2 (en) method for treating a cancer in an individual, drug, kit, method, use or kit, and, method, drug or kit
CL2015002708A1 (en) Heterocyclic compounds and their uses.
MX2016015181A (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer.
EP2968967A4 (en) CONTROL SYSTEM AND FLEXIBLE COILS FOR TREATMENT ADMINISTRATION, FOR EXAMPLE FOR THE TREATMENT OF CANCER
NZ774222A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MX2018011705A (en) Steroid hormone pharmaceutical composition.
PH12017500933A1 (en) Sublingual administration of riluzole
MX2017007707A (en) Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer.
PH12017500934A1 (en) Sublingual formulation of riluzole
PH12017501493A1 (en) Methods of treating infertility
MX364985B (en) Imidazolyl progesterone antagonists.
MX2017000306A (en) Methods for treating hypotension.
MY196276A (en) Isoindole Compounds
MX2015008726A (en) Intracellular phenotypic screening.
UA95103U (en) METHOD OF TREATMENT OF PLACENTARIAL DYSFUNCTION
NZ719745A (en) Soluble fc gamma receptor for treatment of autoimmune bullous diseases
BR112016014099A2 (en) wound treatment method
MX2020005454A (en) Improved treatment of cancer.
MX2020006368A (en) Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
UA85636U (en) Method for treatment of threatened premature birth in pregnant women with multiple pregnancy with spaskurpeldrug
UA76151U (en) METHOD OF PREVENTION OF PLACENTENTIAL DYSFUNCTION IN PREGNANT PREGNANT PREGNANCY
AU2015242879A8 (en) Melatonin secretion regulator, and method for regulating melatonin secretion